Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: Dan Spillane who wrote (2339)	7/27/1999 2:04:00 AM
From: Bindusagar Reddy	Read Replies (1) \| Respond to of 2539

I expect them to report 47-48c upside guidance. GM doing better than most of the street estimates. ROundup is becoming COke of the herbicides. A true brand. Celeberx is going gangbusters with 380-400 milion in revenues. Even non celebrex pharma sales will surprise. We hope stock will rise back to 50.

To: Dan Spillane who wrote (2339)	7/27/1999 8:50:00 AM
From: Exacctnt	Respond to of 2539

Dan, Earnings are out. monsanto.com Regards

To: Dan Spillane who wrote (2339)	7/27/1999 9:29:00 AM
From: Anthony Wong	Respond to of 2539

Monsanto's 2nd-Qtr Profits Rise on Strong Sales of Celebrex Bloomberg News July 27, 1999, 9:00 a.m. ET St. Louis, July 27 (Bloomberg) - The following is a summary of the second-quarter earnings report for Monsanto Co. Expected Market Reaction Limited. Monsanto said profit from continuing operations rose 46 percent to $326 million, or 50 cents a share, from $224 million, or 36 cents, in the year-earlier quarter on sales of its arthritis drug Celebrex. The company was expected to earn 45 cents a share, based on the average estimates of 14 analysts polled by First Call Corp. Estimates ranged from 41 cents to 50 cents. Net sales rose 23 percent to $2.59 billion. The St. Louis-based agricultural chemicals, biotechnology and pharmaceuticals company is the world's second largest maker of crop protection products such as herbicides. Behind the Numbers Though sale of its Roundup herbicides and seeds makes up the bulk of Monsanto's revenue, its chief executive Robert Shapiro told analysts in May second-quarter earnings could exceed Wall Street projections, then 40 cents, because of strong sales of Celebrex. The drug is popular because, unlike ibuprofen and other older pain killers, it's designed to be less likely to cause ulcers. What the Experts Say ''Compared with most pharmaceutical companies, Monsanto is dependent on a select number of products, which makes their earnings more volatile,'' said William Fiala, an analyst with Edward Jones and Co., before the company reported. ''They're also operating from a much smaller base. So Celebrex has a bigger impact.'' ''Celebrex is awesome. We've been expecting it to offset a little bit of weakness in Roundup sales in Latin America,'' Dunkerley said Patrick Dunkerley, an analyst with Securities Corp. of Iowa, who has a ''strong buy'' on Monsanto based on its pharmaceuticals business. Previous Market Reaction Monsanto shares declined 15/16 to 42 1/2 April 22 when the company announced first-quarter profit fell 33 percent to $132 million. Monsanto's first-quarter earnings of 20 cents were 4 cents above the average estimate of analysts polled by First Call. Market Performance Monsanto's shares have dropped 29.5 percent in the last year. Its stock dropped 26.55 percent October 13, the day the company announced it had called off a $35 billion sale to rival American Home Products Corp. Its shares rose 1/8 to 40 Monday.